3. Umbruch 4.4..2005 - Online Pot

20 E. Russo
63 Karnick CR (1996) Ayurvedic narcotic medicinal plants. Sri Satguru Publications, Delhi
64 Clarke RC (1998) Hashish! Red Eye Press, Los Angeles
65 Sharma GK (1977) Ethnobotany and its significance for Cannabis studies in the Himalayas. J
Psychedelic Drugs 9: 337–339
66 Touw M (1981) The religious and medicinal uses of Cannabis in China, India and Tibet. J
Psychoactive Drugs 13: 23–34
67 Chaturvedi GN, Tiwari SK, Rai NP (1981) Medicinal use of opium and cannabis in medieval
India. Indian J History of Science 16: 31–25
68 Chopra RN (1982) Chopra’s indigenous drugs of India. Academic Publishers, Calcutta
69 Ghosh P, Bhattacharya SK (1979) Cannabis-induced potentiation of morphine analgesia in rat –
role of brain monoamines. Indian J Med Res 70: 275–280
70 Majupuria TC, Joshi DP (1988) Religious and useful plants of Nepal and India. M. Gupta,
Lashkar, India
71 Manandhar NP, Manandhar S (2002) Plants and people of Nepal. Timber Press, Portland, OR
72 Chaturvedi GN, Rai NP, Pandey US, Sing KP, Tiwari SK (1991) Clinical survey of cannabis users
in Varanasi. Ancient Science of Life 10: 194–198
73 Gehlot S, Rastogi V, Dubby GP (1996) Role of cannabis extract (tetrahydrocannabinol) for relief
of cancer pain. Sachitra Ayurveda 49: 138–140
74 Zuardi AW, Guimaraes FS (1997) Cannabidiol as an anxiolytic and antipsychotic. In: ML Mathre
(ed.): Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic
use of marijuana. McFarland, Jefferson, NC, 133–141
75 Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ (1997) Effects of dronabinol on anorexia
and disturbed behavior in patients with Alzheimer’s disease. Int J Geriat Psychiat 12: 913–919
76 Deyo RA, Musty RE (2003) A cannabichromene (CBC) extract alters behavioral despair on the
mouse tail suspension test of depression. In: 2003 Symposium on the Cannabinoids. International
Cannabinoid Research Society, Cornwall, ON, Canada, 146
77 Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J,
Hofmann C, Zieglgansberger W et al. (2002) The endogenous cannabinoid system controls extinction
of aversive memories. Nature 418: 530–534
78 Russo EB (2003) Cannabis and cannabis-based medicine extracts: Additional results. J Cannabis
Therapeutics 3: 153–162
79 Wade DT, Robson P, House H, Makela P, Aram J (2003) A preliminary controlled study to determine
whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin
Rehabil 17: 18–26
80 Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmonds S, Sansom C (2004) Initial experiences
with medicinal extracts of cannabis for chronic pain: results from 34 “N of 1” studies.
Anaesthesia 59: 440–452
81 Nicholson AN, Turner C, Stone BM, Robson PJ (2004) Effect of delta-9-tetrahydrocannabinol and
cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin
Psychopharmacol 24: 305–313
82 Mikuriya TH (2004) Cannabis as a substitute for alcohol: a harm-reduction approach. J Cannabis
Therapeutics 4: 79–93
83 Dreher M (2002) Crack heads and roots daughters: The therapeutic use of cannabis in Jamaica. J
Cannabis Therapeutics 2: 121–133
84 Labigalini E Jr, Rodrigues LR, Da Silveira DX (1999) Therapeutic use of cannabis by crack
addicts in Brazil. J Psychoactive Drugs 31: 451–455
85 Mello NK, Mendelson JH (1978) Marihuana, alcohol, and polydrug use: human self-administration
studies. NIDA Res Monogr 93–127
86 Mello NK, Mendelson JH, Kuehnle JC, Sellers ML (1978) Human polydrug use: marihuana and
alcohol. J Pharmacol Exp Ther 207: 922–935
87 Richardson JD, Aanonsen L, Hargreaves KM (1998) Antihyperalgesic effects of spinal cannabinoids.
Eur J Pharmacol 345: 145–153
88 Russo EB (2004) Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic
benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant
conditions? Neuroendocrinol Lett 25: 31–39
89 Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for
treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre
randomised placebo-controlled trial. Lancet 362: 1517–1526